Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) EBITDA Margin (2016 - 2025)

Guided Therapeutics' EBITDA Margin history spans 15 years, with the latest figure at 808.33% for Q3 2025.

  • For Q3 2025, EBITDA Margin changed N/A year-over-year to 808.33%; the TTM value through Sep 2025 reached 1233.15%, up 418791.0%, while the annual FY2024 figure was 30114.29%, 2658673.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 808.33% at Guided Therapeutics, down from 652.14% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 652.14% in Q2 2025 and bottomed at 53300.0% in Q4 2024.
  • The 5-year median for EBITDA Margin is 3831.82% (2023), against an average of 12706.68%.
  • The largest annual shift saw EBITDA Margin surged 1367000bps in 2022 before it crashed -5178438bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 725.0% in 2021, then tumbled by -5528bps to 40800.0% in 2022, then skyrocketed by 96bps to 1515.62% in 2023, then tumbled by -3417bps to 53300.0% in 2024, then skyrocketed by 98bps to 808.33% in 2025.
  • Per Business Quant, the three most recent readings for GTHP's EBITDA Margin are 808.33% (Q3 2025), 652.14% (Q2 2025), and 53300.0% (Q4 2024).